{"entity":{"id":"aebp1","kind":"target","name":"AEBP1","aka":["AE binding protein 1","Adipocyte enhancer-binding protein 1"],"tldr":"AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","summary":"As a positive regulator of collagen fibrillogenesis, it is probably involved in the organisation and remodeling of the extracellular matrix. May positively regulate MAP-kinase activity in adipocytes, leading to enhanced adipocyte proliferation and reduced adipocyte differentiation. May also positively regulate NF-kappa-B activity in macrophages by promoting the phosphorylation and subsequent degradation of I-kappa-B-alpha (NFKBIA), leading to enhanced macrophage inflammatory responsiveness.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Vemurafenib.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:303","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:303"},{"label":"UniProt Q8IUX7","url":"https://www.uniprot.org/uniprotkb/Q8IUX7/entry"},{"label":"NCBI Gene 165","url":"https://www.ncbi.nlm.nih.gov/gene/165"},{"label":"Ensembl ENSG00000106624","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106624"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"AEBP1","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:303","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:303","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q8IUX7","url":"https://www.uniprot.org/uniprotkb/Q8IUX7/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene AEBP1","url":"https://civicdb.org/features/221","note":"1 evidence items, 0 assertions, 1 variants; diseases: Skin Melanoma (GraphQL API, CC0)"}],"hgnc":"HGNC:303","ensembl":"ENSG00000106624","uniprot":"Q8IUX7","entrez":"165","biology":"As a positive regulator of collagen fibrillogenesis, it is probably involved in the organisation and remodeling of the extracellular matrix. May positively regulate MAP-kinase activity in adipocytes, leading to enhanced adipocyte proliferation and reduced adipocyte differentiation. May also positively regulate NF-kappa-B activity in macrophages by promoting the phosphorylation and subsequent degradation of I-kappa-B-alpha (NFKBIA), leading to enhanced macrophage inflammatory responsiveness. Can act as a transcriptional repressor. Location: Secreted; Cytoplasm; Nucleus (UniProt). Locus 7p13 (HGNC).","whereFound":["Melanoma: CIViC evidence names this disease"],"targetClass":"transcription","prevalence":[]},"route":"/targets/aebp1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}]}}